Add to a list

Inactive Instrument

NEOPROBE Stock OTC Bulletin Board

NEOP

US6405181065

Biotechnology & Medical Research

OTC Markets Traded

End-of-day quote OTC Bulletin Board
- ^USD	-

01-30	Motion for Asset Sale Approved for Navidea Biopharmaceuticals, Inc.	CI
01-27	Notice of Asset Purchase Agreement Filed by Navidea Biopharmaceuticals, Inc.	CI

Navidea Biopharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It is developing multiple precision-targeted products based on its Manocept platform to enhance patient care by identifying the sites and pathways of undetected disease. The Companyâ€™s business is focused on two primary types of drug products, such as diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of its Manocept platform, and therapeutic development programs, including therapeutic applications of its Manocept platform. It has developed processes for producing the first four therapeutic Manocept immuno-construct series, the Manocept doxorubicin (MAN-DOX) series, which is designed to specifically target and kill or modify activated CD206+ macrophages by delivering doxorubicin, a Manocept paclitaxel series (MAN-PAC), and a Manocept Bisphosphonate series (MAN-BIS).

Employees

Sector

Biotechnology & Medical Research

More about the company

As early as today, start finding the best investment opportunities!

Market Cap	5.52M 4.93M 4.59M 4.17M 7.88M 534M 7.91M 55.19M 21.63M 272M 20.73M 20.27M 874M	P/E 2021	-2.5x	P/E 2022	-0.38x
Enterprise Value	5.96M 5.32M 4.95M 4.5M 8.5M 577M 8.54M 59.59M 23.35M 294M 22.38M 21.89M 944M	EV / Sales 2021	50.2x	EV / Sales 2022	110x
Free-Float	100%	Yield 2021 *	-	Yield 2022	-

01-30	Motion for Asset Sale Approved for Navidea Biopharmaceuticals, Inc.	CI
01-27	Notice of Asset Purchase Agreement Filed by Navidea Biopharmaceuticals, Inc.	CI
01-23	Notice of Successful Bidder Filed by Navidea Biopharmaceuticals, Inc.	CI
12-29	Reorganization Plan Filed by Navidea Biopharmaceuticals, Inc.	CI
12-10	Bidding Procedure Approved for Navidea Biopharmaceuticals, Inc.	CI
11-23	Motion for Asset Sale Filed by Navidea Biopharmaceuticals, Inc.	CI
11-07	Motion for Case Dismissal or Order Limiting the Debtor-in-Possession?s Powers, Equitably Subordinating Certain Claims or Expanding the Subchapter V Trustee?s Powers Withdrawn for Navidea Biopharmaceuticals, Inc.	CI
11-06	Final DIP Financing Approved for Navidea Biopharmaceuticals, Inc.	CI
11-03	Motion for Case Dismissal or Order Limiting the Debtor-in-Possession?s Powers, Equitably Subordinating Certain Claims or Expanding the Subchapter V Trustee?s Powers Filed for Navidea Biopharmaceuticals, Inc.	CI
25-10-09	Interim DIP Financing Approved for Navidea Biopharmaceuticals, Inc.	CI
25-10-08	Navidea Biopharmaceuticals files for bankruptcy	RE
25-10-01	Navidea Biopharmaceuticals, Inc. Filed for Bankruptcy	CI
24-07-03	Navidea Biopharmaceuticals, Inc. Announces Results of Exploratory Analysis Completed on July 2, 2024	CI

25-10-09	Navidea Biopharmaceuticals Inc. Files for Bankruptcy	AQ
23-12-04	Navidea Biopharmaceuticals, Inc. and Capital Royalty Partners II, L.P. Enter Binding Settlement Agreement and Mutual Release	AQ
23-11-15	Navidea: Q3 Earnings Snapshot	AQ
23-10-05	Navidea Biopharmaceuticals, Inc. Announces NYSE American’s Decision to Suspend Trading In Its Common Stock	BU
23-08-10	Navidea Biopharmaceuticals, Inc. NAVB Requests Oral Hearing With NYSE Hearing Panel	BU

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
WUXI APPTEC CO., LTD.	-2.59%	-5.70%	+50.69%	+86.86%	70.61B
ARGENX SE	+3.23%	-10.67%	+6.27%	+53.70%	51.01B
LONZA GROUP AG	+1.56%	+1.17%	+8.49%	+31.81%	48.1B
IQVIA HOLDINGS INC.	+0.39%	+0.65%	+31.14%	+28.97%	42.78B
REVOLUTION MEDICINES, INC.	+0.87%	-8.17%	+293.37%	+642.41%	40.67B
BEONE MEDICINES AG	+1.24%	-1.01%	+10.74%	+100.64%	40.3B
CELLTRION, INC.	-2.13%	-1.64%	+8.63%	+46.88%	30.59B
WUXI BIOLOGICS (CAYMAN) INC.	-0.46%	-1.28%	+42.23%	+20.34%	28.16B
BIONTECH SE	+5.32%	+0.06%	-5.00%	-12.78%	24.36B
Average	+0.83%	-2.66%	+49.62%	+110.98%	41.84B
Weighted average by Cap.	+0.56%	-2.94%	+51.35%	+115.57%

	2021	2022
Net sales	532K 475K 442K 402K 758K 51.44M 762K 5.31M 2.08M 26.23M 2M 1.95M 84.16M	65.65K 58.63K 54.54K 49.61K 93.67K 6.35M 94.08K 656K 257K 3.24M 247K 241K 10.4M
Net income	-11.73M -10.48M -9.75M -8.86M -16.74M -1.14B -16.81M -117M -45.96M -579M -44.05M -43.09M -1.86B	-15.18M -13.55M -12.61M -11.47M -21.66M -1.47B -21.75M -152M -59.46M -749M -56.99M -55.75M -2.4B
Net Debt	-3.48M -3.11M -2.89M -2.63M -4.97M -337M -4.99M -34.81M -13.64M -172M -13.07M -12.79M -551M	440K 393K 365K 332K 627K 42.56M 630K 4.4M 1.72M 21.7M 1.65M 1.62M 69.63M

NEOPROBE Stock OTC Bulletin Board

Stocks

NEOP

US6405181065

Biotechnology & Medical Research

Valuation: NEOPROBE

Latest news: NEOPROBE

Press Releases: NEOPROBE

Managers and Directors: NEOPROBE

Other Biotechnology & Medical Research

Financials

Company Profile